NCT06636500CompletedPhase 1
A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of CG001419 Administered Orally to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects
Cullgen Australia Pty Ltd1 site in 1 country72 target enrollmentStarted: January 22, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- To evaluate the safety and tolerability of single and multiple ascending oral doses of CG001419 in healthy subjects
Study Overview
Brief Summary
This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Cis-male and cis-female subjects must be 18-65 years, inclusive, at the time of signing the informed consent form (ICF).
- •Subjects who are in good general health according to the judgment of the investigator per local guidance, eg, with no clinically relevant abnormalities based on medical history, physical examinations, neurological examinations, clinical laboratory evaluations (hematology and clinical chemistry), vital signs, and 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, would affect subject safety.
- •Subjects who have a body mass index (BMI) of 18-32 kg/m2 (inclusive) at screening.
- •Male subjects are eligible to participate if they are permanently sterile by vasectomy (at least 6 months), or agree to the following during the study and for at least 90 days after the last dose of study drug:
- •Refrain from donating sperm
- •AND, either:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
- •Agree to use a male condom (contraception/barrier) and should also be advised of the benefit for a female partner to use an acceptable, highly effective method of contraception (of low user dependency or is user dependent), as a condom may break or leak when having sexual intercourse
- •Female subjects are eligible to participate if they are not pregnant or breastfeeding and fall under 1 of the following criteria:
- •Women of childbearing potential (WOCBP), defined as women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test on Day -1; WOCBP must agree to be abstinent from heterosexual intercourse or use an acceptable, highly effective contraceptive method (of low user dependency or is user dependent) from Screening and not donate eggs until 30 days after the last dose of the study drug.
- •Menopausal women must have an elevated serum follicle-stimulating hormone level (FSH >40 IU/mL) level at Screening; if the FSH is not elevated, they are considered to be of childbearing potential (unless permanently sterile).
Exclusion Criteria
- •Clinically significant infection and/or cardiovascular, hematological, renal, hepatic, pulmonary (except recovered childhood asthma), endocrine, reproductive, gastrointestinal, immunological, dermatological, neurological (except migraine), or psychiatric (except depression, which was potentially medicated in the past but didn't require hospitalization) diseases, which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator, unacceptably increase the subject's risk if he/she were to participate in the study.
- •History of neuropathy and/or any neurosensory symptoms in the feet or hands.
- •Unable to ingest a high-fat meal, such as those who are lactose intolerant (only for subjects in the FE part and if recommended, MAD part too)
- •History of disorders that affect gastrointestinal transit time (eg, short bowel syndrome, gastroparesis, irritable bowel syndrome, inflammatory bowel diseases, history of gastric bypass
- •Use of prescription drugs, over-the-counter drugs (other than acetaminophen and ibuprofen), herbal medications, or vitamin supplements within 7 days or 5 half-lives, whichever is longer, prior to dosing and antibiotics and systemic steroids within 30 days prior to dosing. Oral contraceptives are permitted. The sponsor, after consulting medical monitor may allow exceptions only if the medication's administration is deemed unlikely to impact the PK results.
- •Past or current history or evidence of drug or alcohol abuse, alcohol consumption exceeding 5 units of alcohol on an average per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%). Use of any non-marijuana illicit drugs (e.g., cocaine, phencyclidine) within 6 months of Screening.
- •Donation of over 500 mL of blood within 8 weeks prior to Screening.
- •In the opinion of the investigator the subject is unlikely to comply with the study procedures, restrictions, and requirements and is not suitable for entry into the study.
Arms & Interventions
Placebo
Placebo Comparator
Part A: Single ascending dose cohorts; Part B: Multiple ascending dose cohorts
Intervention: Placebo (Drug)
CG001419
Experimental
Part A: Single ascending dose cohorts; food effect cohort; Part B: Multiple ascending dose cohorts
Intervention: CG001419 (Drug)
Outcomes
Primary Outcomes
To evaluate the safety and tolerability of single and multiple ascending oral doses of CG001419 in healthy subjects
Time Frame: Up to 7 days of dosing
Safety and tolerability based on adverse events (AEs)
Secondary Outcomes
- To further characterize the PK of CG001419 in healthy subjects(Up to 7 days of dosing)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
Study of Safety and Biomarker Efficacy of TS23 in Healthy VolunteerCerebral IschemiaPulmonary EmbolismThrombosisMyocardial InfarctionVenous ThrombosisNCT03001544Translational Sciences, Inc.24
Completed
Phase 1
A Study to Assess NEU-411 in Healthy ParticipantsHealthyNCT05755191Neuron23 Inc.147
Completed
Phase 1
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With SchizophreniaSchizophreniaNCT06276361Rovi Pharmaceuticals Laboratories58
Completed
Phase 1
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPostbariatric HypoglycemiaNCT06036784MBX Biosciences69
Completed
Phase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult SubjectsHealthy VolunteersNCT03108755Astellas Pharma Europe B.V.40
Related News
Cullgen Completes Phase 1 Enrollment for Novel Non-Opioid Pain Therapy CG001419- Cullgen has completed enrollment in its Phase 1 clinical trial for CG001419, a potential first-in-class oral pan-TRK protein degrader designed to treat pain without opioid addiction risks.
- The randomized, placebo-controlled trial in healthy volunteers evaluates the safety, tolerability and pharmacokinetic characteristics of this novel non-opioid, non-NSAID analgesic therapy.
- The company plans to file an IND with the FDA and initiate Phase 2 trials for CG001419 in pain management by early 2026.
- CG001419 represents a new class of pain signal inhibitors that could offer patients with acute and chronic pain a safer alternative to current pharmaceutical therapies.last yearCullgen Launches Phase 1 Trial of Novel Non-Opioid Pain Treatment Using Protein Degradation TechnologyCullgen Inc. has initiated Phase 1 dosing of CG001419, a first-in-class oral pan-TRK protein degrader designed to treat acute and chronic pain without the addiction risks associated with opioids. The randomized, placebo-controlled trial in Australia will evaluate the safety, tolerability, and pharmacokinetics of this innovative non-opioid, non-NSAID analgesic therapy.last year